CSIMarket Company Name, Ticker, Industry, else..
 
Affimed N v   (NASDAQ: AFMD)
Other Ticker:  
 
 
Price: $0.7210 $-0.07 -8.838%
Day's High: $0.79 Week Perf: 15.36 %
Day's Low: $ 0.72 30 Day Perf: -19.8 %
Volume (M): 77 52 Wk High: $ 8.95
Volume (M$): $ 56 52 Wk Avg: $3.24
Open: $0.77 52 Wk Low: $0.52



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) -
 Employees 102
 Revenues (TTM) (Millions $) 9
 Net Income (TTM) (Millions $) -119
 Cash Flow (TTM) (Millions $) 213
 Capital Exp. (TTM) (Millions $) 4

Affimed N V
Affimed N.V. is a biopharmaceutical company that specializes in the development of innovative antibody-based immunotherapies for the treatment of cancer and other diseases. The company's proprietary technology platform, called ROCK (Redirected Optimized Cell Killing), enables the engineering of antibodies that can selectively target and destroy cancer cells while sparing healthy cells. With a focus on natural killer (NK) cells, Affimed is developing a pipeline of product candidates that have the potential to improve outcomes for patients with various types of cancer. The company is committed to advancing its therapies through clinical trials and bringing them to market to address unmet medical needs.


   Company Address: Gottlieb-Daimler-Stra?e 2 Mannheim 68165 NY
   Company Phone Number: 621-56003-0   Stock Exchange / Ticker: NASDAQ AFMD


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV   -1.18%    
AZN        1.66% 
JNJ        3.78% 
MRK   -1.49%    
NVS        5.85% 
SNY   -1.19%    
• View Complete Report
   



Clinical Study

Promising Clinical Results in NSCLC Affimeds AFM24/Atezolizumab Combination Therapy Shows Enhanced Efficacy and Sa...

Published Sun, Dec 29 2024 3:53 PM UTC

In a noteworthy development for the treatment of non-small cell lung cancer (NSCLC), Affimed N.V. (Nasdaq: AFMD) has announced encouraging clinical updates from their ongoing AFM24-102 trial, evaluating the combination therapy of AFM24 with atezolizumab. This clinical-stage immuno-oncology company, headquartered in Mannheim, Germany, is focused on leveraging the innate abili...
Product Service News

Affimeds Strategic Double Play FDA Designation and Financial Resilience Set Stage for Growth,

Published Thu, Dec 5 2024 11:30 AM UTC

In a compelling intersection of innovation and financial resilience, Affimed N.V. recently announced two significant developments that may reshape its profile in the biopharmaceutical landscape. The U.S. Food and Drug Administration (FDA) has granted its investigational combination therapy, Acimtamig and AlloNK, the coveted Regenerative Medicine Advanced Therapy (RMAT) desig...
Announcement

Affimed N.V. (Nasdaq AFMD), a clinical-stage immuno-oncology pioneer, is poised to make a significant impac...

Published Tue, Nov 5 2024 2:00 PM UTC

Frontline Progress Against Cancer: Affimed to Showcase Promising Clinical Advances at 2024 ASH Annual Meeting Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology pioneer, is poised to make a significant impact at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, held from December 7-10, 2024, in San Diego, California. The German-based bio...
Clinical Study

Promising Results from Affimeds AFM24 Study in NSCLC Patients with EGFR Mutations and Wild-Type

Published Sat, Jun 1 2024 5:02 PM UTC

CSIMarket.com - June 01, 2024: Affimed N.V., a leading clinical-stage immuno-oncology company, has provided updated follow-up data from its AFM24-102 study in non-small cell lung cancer (NSCLC). The data reveal durable responses in heavily pretreated NSCLC patients with EGFR wild-type (EGFRwt) and positive initial clinical efficacy in the NSCLC EGFR mutant (EGFRmut) cohort...
Product Service News

Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024

Published Thu, May 23 2024 9:05 PM UTC

Affimed Announces Promising Interim Results for AFM24-102 Study in EGFR Wild-Type NSCLC and Revenue Growth at ASCO 2024 Mannheim, Germany May 23, 2024 Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company, has shared encouraging early efficacy and progression-free survival (PFS) results from its AFM24-102 study targeting advanced epidermal growth factor...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com